Scholar Rock stated Wednesday that its investigational remedy helped protect lean mass amongst sufferers taking a robust weight reduction drug, as issues develop that sufferers taking new weight problems therapies could also be shedding an excessive amount of muscle.
A Section 2 trial examined the drug, apitegromab, together with Eli Lilly’s Zepbound. Over 24 weeks, sufferers taking the mix misplaced 12.3% of their weight — 14.6% of which was lean mass and 85.3% of which was fats mass. Compared, sufferers taking placebo with Zepbound misplaced 13.4% of their weight — 30.2% of which was lean mass and 69.5% of which was fats mass.
Apitegromab is an antibody that blocks myostatin, a protein that regulates muscle mass. The examine was meant to be a proof-of-concept trial to ascertain that apitegromab’s mechanism works in sufferers with weight problems.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
